Luis Paz-Ares Rodriguez

33PUBLICATIONS
363CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PsychophysiologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Aug 10, 2026
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

|Jun 29, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|Jun 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

|Jun 01, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jan 16, 2026
NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum.

Sara Bernardo, Lisa Brunet, Quentin Dominique Thomas

Pageof 6

Frequent Collaborators

12 joint publications

Enriqueta Felip

7 joint publications

Byoung Chul Cho

5 joint publications

Marina Garassino

5 joint publications

James Chih-Hsin Yang